Chinese Academy of Medical Sciences

GnRH-a suppresses estrogen and endometrial hyperplasia, inhibits endometrial cancer cell growth. AIs reduce estrogen levels, treating hyperplasia and early cancer. LNG-IUD treats menorrhagia and prevents hyperplasia. Systemic progestogen therapy treats hormone-sensitive hyperplasia and tumors but has low compliance due to adverse effects. Adverse events are managed according to clinical practice guidelines. Trial treatment discontinuation criteria include participant refusal, study cancellation, protocol violation, lack of remission, severe adverse events, and physician judgment. Long-term follow-up is conducted, with statistical analysis using SPSS, focusing on complete response rates, pregnancy outcomes, and adverse events. Data management ensures quality, security, and storage. Results will be published in medical journals.